Adenosine受體(A2ａ/A2b)拮抗劑-開發平台分析:2022年

Adenosine Receptors (A2a/A2b) Antagonists-Pipeline Analytics 2022

出版日期: 2022年12月01日 | 出版商:

Mellalta Meets LLP | 英文 188 Pages | 訂單完成後即時交付

價格

簡介目錄

本報告提供Adenosine受體(A2ａ/A2b)拮抗劑的市場機會，主要競爭分析，企業的開發平台醫藥品簡介，臨床試驗，其他的發展趨勢等彙整資料。

樣本圖

A2aR/A2bR拮抗劑的開發- 概要
開發中產品，各開發階段
A2aR/A2bR拮抗劑的競爭情形情形，各相
開發中產品，各企業
開發中產品，適應症及各相
A2aR/A2bR拮抗劑臨床及法規單劑療法及聯合治療
A2aR/A2bR拮抗劑MOA各類型產品
A2aR/A2bR拮抗劑- 適應症/各相資產
A2aR/A2bR拮抗劑臨床及法規的時間軸

A2aR/A2bR拮抗劑的授權供給，收購，及合作契約

A2aR/A2bR拮抗劑開發平台狀況

簡介比較概要
A2aR/A2bR拮抗劑開發平台的藥物簡介
- 第二階段
  - PBF 999
  - Etrumadenant
  - Imaradenant
  - Taminadenant
  - Inupadenant
- 第一/二階段
  - Ciforadenant
  - TT 702
  - PORT-6
  - PORT-7
- 第一階段
  - CS 3005
  - EXS21546
  - INCB 106385
  - INT 1B3
  - PBF 1129
  - M-1069
  - ILB-2109
  - DZD2269
- 前臨床
  - ARX 001822
  - Vipadenant
  - PORT-9
  - PORT-8
  - CPI-395
- 藥物研發
  - A2AR拮抗劑
  - LNC-001
  - LNC-002
  - LNC-003
  - RT-AR001

A2aR/A2bR拮抗劑產品的定位

矩陣分析

附錄

簡介目錄

Product Code: MM1114729

The Adenosine Receptors (A2a/A2b) Antagonists report covers the Adenosine Receptors (A2a/A2b) Antagonists market opportunity providing Key Competitive Analysis, 24+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. The report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area, and indication by phases. The Adenosine Receptors (A2a/A2b) Antagonists report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

SAMPLE VIEW

Adenosine is involved in a range of physiological and pathological effects through membrane-bound receptors linked to G proteins. There are four subtypes of adenosine receptors, described as A1AR, A2AAR, A2BAR, and A3AR, which are the center of cAMP signal pathway-based drug development. Several types of agonists, partial agonists or antagonists, and allosteric substances have been synthesized from these receptors as new therapeutic drug candidates. AR agonists for treating inflammation, pain, cancer, non-alcoholic steatohepatitis, angina, sickle cell disease, ischemic conditions, and diabetes have been under development.

In this report, Mellalta Meets provides an in-depth analysis of Adenosine Receptors (A2a/A2b) Antagonists covering discovery, preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 27 candidate Adenosine Receptors (A2a/A2b) Antagonists products currently under evaluation in clinical and preclinical studies. The major key players operating in the market are Palobiofarma, Arcus Biosciences/Gilead Sciences, AstraZeneca/Sosei Heptares, Novartis/Palobiofarma, iTeos Therapeutics, Corvus Pharmaceuticals/Angel Pharmaceuticals.

As per analysis, A2AR/A2B Receptor inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME), and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing with the development pipeline full of molecules like small molecules, and combination therapies.

Key Highlights of the Adenosine Receptors (A2a/A2b) Antagonists Report:

There are ~8 products in the Phase 1 stage of development, representing 29.63% of the total share of the developing A2aR/A2bR Antagonist landscape. The remaining 70.37% has been contributed by Phase 2 (18.52%), Phase 1/2 (14.81), Pre-clinical (18.52%), and Discovery (18.52%) assets.

The pipeline of Adenosine Receptors (A2a/A2b) Antagonists is dominated by biotech companies headquartered in the United States with American companies holding the top 9 positions. They represent ~37.50% of all the pipeline Adenosine Receptors (A2a/A2b) Antagonists in clinical stages.

Adenosine Receptors (A2a/A2b) Antagonists pipeline landscape includes 67% of Monotherapy trials and 33% of Combination Trials

The pipeline of Adenosine Receptors (A2a/A2b) Antagonists is dominated by Phase 1 (8), Phase 2 (5), Phase 1/2 (4), Pre-clinical (5), and Discovery (5) assets.

To be continued.....

Report Coverage:

Indication Prioritisation: Adenosine Receptors (A2a/A2b) Antagonists market potential based on Indications

Business Transactions & Strategies: Key collaborations and deal values

Adenosine Receptors (A2a/A2b) Antagonists Pipeline Development: Product Profiles, Clinical Trials & Results

Adenosine Receptors (A2a/A2b) Antagonists Acquisition Targets

Adenosine Receptors (A2a/A2b) Antagonists Competitive Intelligence

Recent & Upcoming events

OVERVIEW

The A2aR/A2bR Antagonist Target BACKGROUND

A2A/A2B Adenosine Receptor Antagonist-Overview
Adenosine-A2A Receptor Pathway in Cancer Immunotherapy
A2AR Antagonist and Clinical Progress
A2B Adenosine Receptor (A2BAR) and Cancer
Future Directions
Key Lessons from the clinical trials targeting the adenosine pathway

A2aR/A2bR Antagonists PIPELINE ANALYSIS by Phases

A2aR/A2bR Antagonists Development - Overview
Pipeline Products by Stage of Development
A2aR/A2bR Antagonists Competitive Landscape by Phases
Pipeline Products by Company
Pipeline Products by Indication and Phases
A2aR/A2bR Antagonists Clinical & Regulatory Monotherapy & Combinations
A2aR/A2bR Antagonists Products by MOA type
A2aR/A2bR Antagonists- Assets by Indication/Phase
A2aR/A2bR Antagonists Clinical & Regulatory Timelines

A2aR/A2bR Antagonists LICENSING, ACQUISITION, AND COLLABORATION DEALS

A2aR/A2bR Antagonist Licensing, Acquisition, and Deal values
A2aR/A2bR Antagonist Licensing by Transaction type and total amount size by Phases

A2aR/A2bR Antagonists Pipeline Landscape

Profile Comparisons At-a-glance
A2aR/A2bR Antagonist Pipeline Drug Profiles
- Phase II
  - PBF 999 (Palobiofarma)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - Etrumadenant (Arcus Biosciences/Gilead Sciences)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - Imaradenant (AstraZeneca/Sosei Heptares)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - Taminadenant (Novartis; Palobiofarma)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - Inupadenant (iTeos Therapeutics)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
- Phase I/II
  - Ciforadenant (Corvus Pharmaceuticals; Genentech; Vernalis)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - TT 702 (Teon Therapeutics)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - PORT-6 (Portage Biotech)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - PORT-7 (Portage Biotech)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
- Phase I
  - CS 3005 (CStone Pharmaceuticals)
    - Product Profile & Description
    - Clinical Trials
    - Other Developments
  - EXS21546 (Exscientia, Evotec)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - INCB 106385 (Incyte Corporation)
    - Product Profile & Description
    - Clinical Trials
    - Other Developments
  - INT 1B3 (InteRNA Technologies)
    - Product Profile & Description
    - Clinical Trials
    - Other Developments
  - PBF 1129 (Palobiofarma)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - M-1069 (Domain Therapeutics/Merck)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - ILB-2109 (Innolake Biopharma)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
  - DZD2269 (Dizal Pharma)
    - Product Profile & Description
    - Clinical Trials
    - Collaborations
    - Other Developments
- Pre-clinical
  - ARX 001822 (AdoRx Therapeutics)
    - Product Profile & Description
    - Collaborations
    - Other Developments
  - Vipadenant (BMS)
    - Product Profile & Description
    - Collaborations
    - Other Developments
  - PORT-9 (Portage Biotech)
    - Product Profile & Description
    - Other Developments
  - PORT-8 (Portage Biotech)
    - Product Profile & Description
    - Other Developments
  - CPI-395 (Corvus Pharmaceuticals)
    - Product Profile & Description
    - Other Developments
- Discovery
  - A2AR antagonist (Hanmi Pharmaceuticals)
    - Product Profile & Description
    - Other Developments
  - LNC-001 (Lewis & Clark Pharmaceuticals)
    - Product Profile & Description
    - Collaborations
    - Other Developments
  - LNC-002 (Lewis & Clark Pharmaceuticals)
    - Product Profile & Description
    - Collaborations
    - Other Developments
  - LNC-003 (Lewis & Clark Pharmaceuticals)
    - Product Profile & Description
    - Collaborations
    - Other Developments
  - RT-AR001 (Lewis & Clark Pharmaceuticals)
    - Product Profile & Description
    - Collaborations
    - Other Developments
    - A2aR/A2bR Antagonists SWOT Analysis